Study of Efficacy and Safety of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)

NCT04390763 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

164

Enrollment

INDUSTRY

Sponsor class

Stopped The study was early terminated following the NIS793 treatment halt and urgent safety measure issued in July 2023, as the continued evaluation of Standard of Care alone will not support the original purpose of this phase 2 clinical trial.

Conditions

Metastatic Pancreatic Ductal Adenocarcinoma

Interventions

BIOLOGICAL: NIS793
BIOLOGICAL: Spartalizumab
DRUG: gemcitabine
DRUG: nab-paclitaxel

Sponsor

Novartis Pharmaceuticals